Intradigm Corporation Obtains $21,400,000 Series B Financing Round

  • Feed Type
  • Date
    1/7/2009
  • Company Name
    Intradigm Corporation
  • Mailing Address
    3350 W Bayshore Rd Palo Alto, CA 94303
  • Company Description
    Our Mission:

    “To deliver the promise of RNA interference (RNAi) therapeutics for the treatment of human diseases with unmet medical needs through our advanced targeted systemic delivery technology with an initial focus on oncology therapeutics.”

  • Website
    http://www.intradigm.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $21,400,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Intradigm will use Series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.intellectual property, as well as its RNAi Nanoplex (NPX) delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.
  • M&A Terms
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Astellas Venture Capital

By posting a comment, you agree to our terms and conditions.